Market Closed -
Other stock markets
|
After market 06:30:10 pm | |||
147.1 USD | +0.45% | 147.4 | +0.23% |
12:18am | Top law firms in US opioid lawsuits to get hundreds of millions in fees | RE |
Jun. 07 | J&J-backed Rapport Therapeutics shares debut nearly 6% higher | RE |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's enterprise value to sales, at 3.93 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.16% | 354B | C+ | ||
+45.82% | 765B | C+ | ||
+40.95% | 632B | B | ||
+19.86% | 331B | B- | ||
+9.32% | 299B | C+ | ||
+18.45% | 248B | B+ | ||
+11.88% | 216B | B- | ||
-0.78% | 219B | A+ | ||
+5.90% | 164B | C+ | ||
-0.73% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- Ratings Johnson & Johnson